Insider · CIK 0001892397
Jill Ann Howe
Files at LCTX (Lineage Cell Therapeutics, Inc.), BIOR (BIORA THERAPEUTICS, INC.). First filing Aug 19, 2024, latest Nov 26, 2024.
In brief
Jill Ann Howe files SEC Form 4 as CFO and director at LCTX (Lineage Cell Therapeutics, Inc.), and also at BIOR (BIORA THERAPEUTICS, INC.). Since Aug 19, 2024, Jill Ann Howe has reported 2 open-market buys worth $18k and 0 open-market sells worth $0, the latest filed on Nov 26, 2024.
A track record needs three past buys with six months of prices behind them; Jill Ann Howe has 1, so none is measured yet.
The newest scored trade: bought $8,850 of LCTX on Nov 26, 2024, filed Nov 26, 2024, scored 47 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LCTX: Lineage Cell Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Lineage Cell Therapeutics, Inc. | $8,850 15,000 shares | +143% | - | |
| 48Moderate | LCTXbuy Lineage Cell Therapeutics, Inc. | $9,345 10,500 shares | - | +8% from low-42% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,050,000 | $0.00 | $0 | 1,050,000 | Mar 6, 2026 |
| Mar 10, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Mar 12, 2025 |
| Nov 26, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +15,000 | $0.59 | $8,850 | 25,500 | Nov 26, 2024 |
| Aug 16, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +10,500 | $0.89 | $9,345 | 10,500 | Aug 19, 2024 |
| Jun 5, 2024 | BIOR BIORA THERAPEUTICS, INC. | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 31,916 | Jun 6, 2024 |
| Jun 5, 2024 | BIOR BIORA THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Jun 6, 2024 |
| Mar 7, 2024 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Mar 8, 2024 |
Questions about Jill Ann Howe
Answered from the filings on this page, as of the latest one.
Is Jill Ann Howe buying or selling?
Not in the last 12 months. Jill Ann Howe's latest open-market trade on SEC Form 4 was bought $8,850 of LCTX on Nov 26, 2024.
How did Jill Ann Howe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jill Ann Howe has 1.
Where does Jill Ann Howe file Form 4?
Jill Ann Howe has filed Form 4 at LCTX (Lineage Cell Therapeutics, Inc.) as Chief Financial Officer; BIOR (BIORA THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.